Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Discovery of a new gene involved in an early and very severe form of Parkinson's disease

Published on: 04/03/2016 Reading time: 1 min
pipettage
Retour à la recherche

Pr. Alexis Brice's team at the Brain and Spine Institute – Inserm / CNRS / UPMC, in collaboration with two international consortia has identified a new gene, VPS13C, involved in an early form of Parkinson's disease. Mutations in VPS13C lead to a loss of function of the corresponding protein. This protein may play a key role in neuron protection through the maintenance of mitochondrial function. These results provide a better understanding of the mechanisms leading to neuron degeneration, thus opening the way to new therapeutic approaches. Moreover, they will enable the establishment of a diagnostic tool for these very severe forms of the disease, in order to manage them as quickly as possible.

The genetic cause of nearly half of early forms of Parkinson's disease has not yet been elucidated. Through high-throughput DNA sequencing from 62 people with a form of early and consanguineous Parkinson's disease, Suzanne Lesage and her staff have identified a new gene involved, VPS13C. Mutations in this gene are associated with a very characteristic form of the disease which develops early (before 40), evolving quite rapidly (aggravation of motor symptoms leading to severe disability) and is accompanied by cognitive impairment. Mutations of this gene are harmful and lead to a loss of function of the corresponding protein.

In Parkinson's disease, degeneration of a specific population of neurons, dopaminergic neurons, would be due, in part, to a dysfunction of mitochondria, equivalent to the powerhouse of the cell. Indeed, in some forms of Parkinson's disease, dopamine neurons' death is caused by mutations in PINK1 and PARK2 genes, coding for proteins which function is to preserve mitochondria quality. The good functioning and survival of neurons works, among other things, via degradation (or mitophagy) and replacement of defective mitochondria. Both proteins, PINK1 and PARKIN are involved in this process.

Data collected in cellular models by Olga Corti and her staff in Alexis Brice's team, suggest that the loss of function of VPS13C protein increases the vulnerability of mitochondria to stress, which leads to the activation of PINK1/PARKIN pathway in order to preserve their activity. VPS13C role in mitochondria protection and its relationship with PINK1/PARKIN dependent mitophagy remain to be explained.

This work highlights a new gene associated to a very severe form of the disease which loss of function would lead to mitochondrial dysfunction. They enable a better understanding of signalling pathways impacting mitochondrial function, and pave the way for the discovery of new therapeutic leads. Moreover, the possibility of a reliable molecular diagnosis for this severe form of the disease will allow faster care.

Sources

https://www.cell.com/ajhg/fulltext/S0002-9297(16)00048-3

Our news on the subject

VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
Ne plus penser à rien : vers une signature cérébrale du blanc mental
Not Thinking About Anything: Toward a Brain Signature of Mind Blanking
What if the flow of our thoughts occasionally just stopped? Esteban Munoz-Musat, Lionel Naccache, Thomas Andrillon, and their colleagues at Paris Brain Institute and Monash University in Melbourne show that the sensation of “thinking about nothing”...
12.26.2025 Research, science & health
Deux nouvelles certifications pour les plateformes de l’Institut du Cerveau
Two new certifications for Paris Brain Institute’s core facilities
Paris Brain Institute’s core facilities were recently awarded two new certifications: ISO 9001 certification for ICM.Quant and ISO 20387 certification for its DNA & Cell Bank.
11.14.2025 Institutional
La dépression résistante possède une signature moléculaire spécifique
Treatment-resistant depression identified as a distinct molecular subtype
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave...
11.03.2025 Research, science & health
La qualité des mitochondries durant le neurodéveloppement est cruciale pour la santé cérébrale
Mitochondrial quality during neurodevelopment is crucial for brain health
The anomalies underlying neurodegenerative diseases may arise during development—decades before the first symptoms appear. This hypothesis is gaining traction thanks to a new study published in Nature Communications. According to researchers from the...
10.20.2025 Research, science & health
See all our news